CompletedPhase NA

Research of Intensive Lifestyle Intervention for PCOS Patients With IGT

Research of Intensive Lifestyle Intervention for Overweight PCOS Patients With Impaired Glucose Tolerance in Their Metabolic and Reproductive Abnormalities Treatment

Lead sponsor

RenJi Hospital

Asset

GLP-1 / incretin class catch-all

Listed sites

Recruiting sites

Actual enrollment

Study population

Obesity / overweight

Eligibility highlights

•Female

Primary endpoint

•Changes of Islet β-cell functions

Registered trial locations

Locations reported to ClinicalTrials.gov for this trial snapshot. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT02446834

Org study ID[2015]018K

Timeline

Milestones

Study first posted2015-05-18estimated

Last update posted2022-10-17actual

Study start2015-04actual (month precision)

Primary completion2017-12actual (month precision)

Study completion2018-04actual (month precision)

Assets

Investigational agents

GLP-1 / incretin class catch-all

Who this study enrolls

Obesity / overweight

Who can enroll

Minimum age14 Years

Maximum age50 Years

SexFemale

Healthy volunteersNot accepted

Inclusion criteria

•Overweight and obese PCOS patients with newly diagnosed IGT; PCOS diagnosis based on 1990 NIH criteria. Overweight / obesity diagnostic criteria according to WHO-WPR. IGT diagnostic criteria according to 1998 WHO diagnostic criteria.

Exclusion criteria

•Except for serious complications (cardiovascular events and recent significant kidney or lung disease within 3 months), and had high blood pressure (>160/100mmHg), blood sugar and high blood lipids (glycated hemoglobin> 11%, triglycerides >600 mg/dl).

Endpoints (4)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Other (unclassified)

Weight & body composition

1 endpoint

Secondary/protocol endpoint

Intra-abdominal fat distribution

Time frame:up to 12 weeks

descriptive

Other (unclassified)

3 endpoints

Primary/protocol endpoint/low confidence

changes of Islet β-cell functions from baseline

Time frame:up to 12 weeks

descriptive

Secondary/protocol endpoint/low confidence

Incretin

Time frame:up to 12 weeks

descriptive

Secondary/protocol endpoint/low confidence

Sex Hormone

Time frame:up to 12 weeks

descriptive

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2

Snapshot dateJuly 6, 2026

Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)

Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 6, 2026 snapshot.